1st ARPA-H Grant: mRNA-Based Anti-Cancer and Anti-Microbial Vaccine Development

Cancer vaccines utilizing mRNA vaccine technology have such potential that ARPA-H, a newly established White House-originated program, has made it the focus of its first ever grant.